Motion Controls & Robotics Software Engineer

Accuray advances strategic priorities through key executive leadership appointments. Aug 12, 2026, 17:09 ET MADISON, Wis., Aug. 12, 2026 /PRNewswire/ - Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth. As part of these efforts, Accuray has named Todd Brown to lead the company's newly created Enterprise Performance Optimization organization and has appointed Sofiane Laoussadi as Senior Vice President, Global Services & Solutions. These leadership appointments reinforce Accuray's previously announced Transformation Phase II priorities of improving operational execution, lowering its cost structure, and creating greater value for customers and shareholders. "These leadership appointments represent an important step in executing the strategic priorities we recently outlined for Accuray," said Steve LaNeve, President and Chief Executive Officer of Accuray. "By enhancing our global services capabilities and establishing a dedicated focus on enterprise performance optimization, we are creating a more agile, performance-driven organization that can respond faster to customer needs and deliver long-term value for shareholders." Optimizing Enterprise Performance To unify systems and processes and improve performance across its business functions and geographies, Accuray has established a new Enterprise Performance Optimization organization and has designated Todd Brown as Senior Vice President to lead it. A veteran of GE Healthcare, where he had been Vice President & General Manager, Healthcare Services, US & Canada, Brown joined Accuray approximately three years ago. Since then, he has successfully driven revenue growth, developed new solutions, and improved performance in the company's services business, which generated 57% of the company's consolidated net revenues in fiscal year 2026. As the leader of the new Enterprise Performance Optimization function, Brown will plan and lead global initiatives focused on improving working capital and cash flow, enhancing supply chain efficiency, optimizing costs, and streamlining processes and systems through digitization. The establishment of the new function and the appointment of an experienced executive to lead it reflect Accuray's commitment to disciplined execution and continuous improvement, helping drive profitable growth through stronger operational performance, a focus on cash flow, and greater organizational accountability. "While leading our services organization, Todd has consistently demonstrated the ability to drive results through collaboration, discipline, and innovation," said LaNeve. "His leadership will help us strengthen execution, improve efficiency, and increase margins while accelerating growth." Advancing Global Services Excellence Laoussadi has more than 20 years of experience leading services, operations, and commercial organizations across healthcare and industrial markets. Also a veteran of GE Healthcare, Laoussadi has been a senior executive at two private equity-backed businesses and, most recently, was President, Pharma, Health & Durables for Klockner Pentaplast. Throughout his career, he has led transformational initiatives that improved operational performance, enhanced customer experiences, and supported profitable growth. As Senior Vice President, Global Services & Solutions, Laoussadi will lead Accuray's global services organization, which has evolved into a solutions-focused business line intended to help customers maximize the value of their technology investments. Supporting our global installed base, he will oversee the delivery of services, customer support, lifecycle management, software upgrade programs, clinical and technical training, workflow consulting, and other high-margin value-added solutions that extend beyond traditional equipment service. His focus will be on enhancing customer experience, driving service innovation, and expanding solution-based offerings that help healthcare providers optimize system performance and deliver high-quality patient care throughout the lifecycle of their Accuray technologies, while supporting Accuray's revenue growth and profit margin expansion. "Sofiane brings a proven track record of building high-performing organizations and delivering measurable improvements in customer and operational outcomes," said LaNeve. "His leadership will further advance our global services capabilities and help us deliver even greater value to healthcare providers worldwide." Positioned for Long-Term Growth Together, these leadership appointments demonstrate Accuray's commitment to the next phase of its transformation strategy, including greater operational discipline and helping radiation therapy providers maximize system utilization, optimize workflows, derive greater value from their technology investments, and deliver exceptional patient care. These efforts will help create greater value for our customers and build long-term value for Accuray's shareholders. "Our focus is clear: deliver exceptional clinical and economic outcomes for customers, operate with discipline and efficiency, and continuously improve how we execute," LaNeve added. "These leadership actions reinforce our foundation for sustainable, profitable growth and long-term value creation." About Accuray Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases-while making commonly treatable cases even easier-to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube. Forward Looking Statement Statements made in this press release that are not statements of historical fact are forward-looking statements that are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, statements regarding Accuray's ability to enhance customer value, improve operational execution and profitability, enhance overall enterprise performance, execute on its strategic priorities, advance its global services and solutions business, attain the expected benefits of the initiatives under the Enterprise Performance Optimization function, strengthen financial performance, deliver long-term value for shareholders, and achieve sustainable, profitable growth. Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "may," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; effects related to international tariffs; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and the company's ability to maintain compliance with financial covenants related to its debt; the successful execution of strategic and operational initiatives; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 6, 2026, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements. Accuray Media Contact Taylor Bould Communications Specialist, Accuray +1 (608) 830-3604 [email protected] SOURCE Accuray Incorporated

T2S Group Holding's $117M IPO oversubcribed 43.75x on Casablanca Stock Exchange. Morocco's integrated MedTech group draws over $5.14 billion in orders, signaling renewed investor confidence in North Africa's equity market and the burgeoning healthcare technology sector. AU-Startups · Burgundy The IPO comprised 4.93 million shares priced at 223 dirhams each, valuing T2S Group Holding at approximately 4.9 billion dirhams ($520 million) post-listing. The offering was structured as a combination of a 350 million dirham capital increase and the sale of 750 million dirhams of existing shares by Trone Investment Holdings, an investment vehicle of Helios Investment Partners. This structure provided both growth capital for the company and liquidity for early investors. Trone Investment Holdings remains the largest shareholder with a 42% stake post-IPO. The overwhelming demand resulted in an average allocation rate of just 2.29% for subscribers, with individual investors accounting for nearly 99% of the total participants. This retail investor enthusiasm, drawing from 81 different nationalities, reflects a growing interest in Moroccan equities, a trend highlighted by the Casablanca Stock Exchange's chief executive, Nasser Seddiqi. Market context and comparables. T2S Group Holding's successful IPO follows a notable resurgence in Casablanca's primary market activity. The exchange saw three IPOs in 2025 - Vicenne in July, construction group SGTM, and fintech Cash Plus in November - after a multi-year drought. The Cash Plus IPO, which raised $82.5 million at a $550 million valuation, was oversubscribed 64 times, setting a high benchmark for subsequent listings. While T2S Group Holding's oversubscription rate of 43.75x is lower than Cash Plus's, it still represents substantial investor confidence, especially considering the MedTech sector's distinct risk profile compared to fintech. Morocco's healthcare sector is undergoing significant reforms, including expanding universal health coverage, which now reaches 88% of the population. The government has committed substantial investment to modernize hospital infrastructure, digitize patient records, and develop local manufacturing of medical products. The African medical devices market is projected to grow from $9.7 billion in 2024 to $14.93 billion by 2033, with Morocco identified as a key market alongside South Africa, Egypt, Nigeria, and Algeria. However, over 90% of medical devices on the continent are imported, indicating a reliance on foreign suppliers and potential vulnerabilities in the supply chain. Operational capabilities and growth trajectory. Founded in 1992 by Abderraouf Sordo, T2S Group Holding has evolved into Morocco's largest integrated medical technology company. The company distributes, installs, and maintains high-tech medical equipment, diagnostic systems, radiopharmaceutical products, and hospital software. It operates across seven segments, including radiology and oncology, medical devices, in vitro diagnostics, and after-sales services, with recurring activities accounting for 46% of its 2025 revenue of 1.76 billion dirhams ($188 million). This diversified model, which emphasizes maintenance contracts and consumables over one-off sales, aims to provide more stable revenue streams. T2S Group Holding has established partnerships with over 40 international MedTech companies, including GE HealthCare, BioMérieux, Boston Scientific, and Accuray, and operates in more than 20 African countries. The company's business plan forecasts an average annual revenue growth of approximately 18% between 2026 and 2030, targeting consolidated revenue of 4.17 billion dirhams ($445 million) by 2030. The skeptical view and what this round buys. While the IPO's oversubscription indicates strong market appetite, the ambitious growth targets for T2S Group Holding warrant scrutiny. The company plans to replicate its Moroccan model across francophone Africa, focusing initially on eight priority countries and relying on radiology, oncology, and after-sales services. Expanding into diverse African markets, each with its own regulatory, logistical, and talent challenges, presents significant operational hurdles. Morocco's healthcare regulatory landscape, while undergoing reform, can still be complex, and navigating varied regulations across multiple African nations will require robust local expertise. The IPO proceeds, approximately 350 million dirhams, will primarily fund the construction of a second cyclotron facility in Fez, the rollout of in-vitro diagnostic equipment, and upgrades to IT systems and cybersecurity. The 2026-2030 investment program totals 336 million dirhams, suggesting that the capital increase provides sufficient runway for these immediate strategic initiatives. However, the ability to attract and retain specialized talent for expansion across Africa, particularly in complex medical technology fields, will be critical. The market will be watching closely to see if T2S Group Holding can translate its domestic success into sustained pan-African growth while maintaining profitability and navigating competitive pressures from both international players and emerging local innovators. Based on information available at time of publication. Trademarks and logos belong to their respective owners. Spot an error? Write to [email protected]. Editorial policy · Disclaimer.

Vision RT and Accuray launch first clinical use of AlignRT InBore on Helical Platform. By News Release Published Date: June 22, 2026 Vision RT and Accuray have announced a significant milestone in the clinical implementation of their AlignRT InBore technology, now successfully utilized on the Accuray Helical Platform. Clinique Générale-Beaulieu, a member of the Swiss Medical Network, is the inaugural institution to employ this innovative solution, setting a precedent in the global medical community. The Swiss Medical Network, comprising three sites and serving approximately 900 patients annually, intends to expand the application of AlignRT InBore for patients undergoing treatment for breast, prostate, gastrointestinal, and secondary cancers. This integration marks an advancement in bore-based helical radiotherapy available at the network's facilities. The AlignRT InBore system combines Vision RT's ceiling-mounted AlignRT camera system, used for patient setup, with a specialized multi-camera configuration mounted inside the treatment bore. This strategic combination ensures that patient visibility and tracking remain uninterrupted during setup, imaging, and treatment phases. Commenting on this development, Vision RT CEO Dr. Norman Smith stated, "AlignRT InBore on the Accuray Helical Platform represents a step further in our mission to make surface guidance universal across radiation therapy." Designed specifically for the Accuray Helical Platform, AlignRT InBore incorporates a 3 mm-thick ring within the bore, facilitating seamless integration into the treatment environment while ensuring continuous surface tracking. Piyush Pratap Singh, Director of Product Marketing at Accuray, emphasized the system's capacity to enhance treatment precision and operational efficiency, noting: "Bringing AlignRT InBore to the Accuray Helical Platform reflects our commitment to expanding a vendor-neutral ecosystem that supports advanced treatment workflows." Professor Oscar Matzinger, Medical Director of Radio-Oncology and Chief Medical Officer of the Swiss Medical Network, expressed pride in their pioneering role, stating, "This achievement reflects the successful collaboration between Vision RT, Accuray, and our department. By enabling continuous patient monitoring and supporting breath-hold treatments, this innovative technology complements the precision of Accuray helical delivery and enhances treatment quality and safety." This integration of AlignRT InBore reaffirms Vision RT's commitment to enhancing radiation therapy for optimized patient care, encompassing simulation, planning, treatment, and dosing processes.